RT Journal Article
SR Electronic
A1 Bittner, Dennis
T1 Exploring the Value and Costs of Incretin-Based Therapies
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 32
SP 34
OP 35
DO 10.1177/155989771432022
UL http://mdc.sagepub.com/content/14/32/34.abstract
AB The development of incretin-based therapies over the past decade since the approval of exenatide has opened new possibilities for the treatment of type 2 diabetes mellitus (T2DM). This article discusses the various metabolic activities of endogenous GLP-1 and DPP-4 antagonists, the side effects of incretin-based therapies, and the need for new diabetes treatments.